AZD8309 is an orally active antagonist of Significantly reduced MPO in the pancreas and lungs (8 h & 24 h) and reduced intrapancreatic trypsin and elastase activity (8 h) in caerulein-pancreatitis.
Reduced serum cytokine levels as well as histopathological damage.
[1]. Malla SR, et al. Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis. Pancreatology. 2016 Sep-Oct;16(5):761-9.